477 related articles for article (PubMed ID: 28790107)
21. JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.
Mansour MR; He S; Li Z; Lobbardi R; Abraham BJ; Hug C; Rahman S; Leon TE; Kuang YY; Zimmerman MW; Blonquist T; Gjini E; Gutierrez A; Tang Q; Garcia-Perez L; Pike-Overzet K; Anders L; Berezovskaya A; Zhou Y; Zon LI; Neuberg D; Fielding AK; Staal FJT; Langenau DM; Sanda T; Young RA; Look AT
J Exp Med; 2018 Jul; 215(7):1929-1945. PubMed ID: 29941549
[TBL] [Abstract][Full Text] [Related]
22. Runx1 is essential at two stages of early murine B-cell development.
Niebuhr B; Kriebitzsch N; Fischer M; Behrens K; Günther T; Alawi M; Bergholz U; Müller U; Roscher S; Ziegler M; Buchholz F; Grundhoff A; Stocking C
Blood; 2013 Jul; 122(3):413-23. PubMed ID: 23704093
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic Runx1-Myc axis in p53-deficient thymic lymphoma.
Date Y; Taniuchi I; Ito K
Gene; 2022 Apr; 819():146234. PubMed ID: 35114276
[TBL] [Abstract][Full Text] [Related]
24. Monoallelic
Veiga DFT; Tremblay M; Gerby B; Herblot S; Haman A; Gendron P; Lemieux S; Zúñiga-Pflücker JC; Hébert J; Cohen JP; Hoang T
Front Immunol; 2022; 13():867443. PubMed ID: 35401501
[TBL] [Abstract][Full Text] [Related]
25. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
[TBL] [Abstract][Full Text] [Related]
26. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.
Della Gatta G; Palomero T; Perez-Garcia A; Ambesi-Impiombato A; Bansal M; Carpenter ZW; De Keersmaecker K; Sole X; Xu L; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Meijerink JP; Califano A; Ferrando AA
Nat Med; 2012 Feb; 18(3):436-40. PubMed ID: 22366949
[TBL] [Abstract][Full Text] [Related]
27. Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia.
Simeoni F; Romero-Camarero I; Camera F; Amaral FMR; Sinclair OJ; Papachristou EK; Spencer GJ; Lie-A-Ling M; Lacaud G; Wiseman DH; Carroll JS; Somervaille TCP
Cell Rep; 2021 Sep; 36(12):109725. PubMed ID: 34551306
[TBL] [Abstract][Full Text] [Related]
28. TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.
Sanda T; Leong WZ
Exp Hematol; 2017 Sep; 53():7-15. PubMed ID: 28652130
[TBL] [Abstract][Full Text] [Related]
29. Runx genes are direct targets of Scl/Tal1 in the yolk sac and fetal liver.
Landry JR; Kinston S; Knezevic K; de Bruijn MF; Wilson N; Nottingham WT; Peitz M; Edenhofer F; Pimanda JE; Ottersbach K; Göttgens B
Blood; 2008 Mar; 111(6):3005-14. PubMed ID: 18184866
[TBL] [Abstract][Full Text] [Related]
30. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
[TBL] [Abstract][Full Text] [Related]
31. ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis.
Leong WZ; Tan SH; Ngoc PCT; Amanda S; Yam AWY; Liau WS; Gong Z; Lawton LN; Tenen DG; Sanda T
Genes Dev; 2017 Dec; 31(23-24):2343-2360. PubMed ID: 29326336
[TBL] [Abstract][Full Text] [Related]
32. Alteration of CTCF-associated chromatin neighborhood inhibits TAL1-driven oncogenic transcription program and leukemogenesis.
Li Y; Liao Z; Luo H; Benyoucef A; Kang Y; Lai Q; Dovat S; Miller B; Chepelev I; Li Y; Zhao K; Brand M; Huang S
Nucleic Acids Res; 2020 Apr; 48(6):3119-3133. PubMed ID: 32086528
[TBL] [Abstract][Full Text] [Related]
33. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
[TBL] [Abstract][Full Text] [Related]
34. ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.
Mertz JA; Kobayashi R; Dudley JP
J Virol; 2007 Apr; 81(7):3503-13. PubMed ID: 17229714
[TBL] [Abstract][Full Text] [Related]
35. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia.
Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
[TBL] [Abstract][Full Text] [Related]
36. Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.
Kilbey A; Terry A; Wotton S; Borland G; Zhang Q; Mackay N; McDonald A; Bell M; Wakelam MJ; Cameron ER; Neil JC
J Cell Biochem; 2017 Jun; 118(6):1432-1441. PubMed ID: 27869314
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.
Nagel S; Venturini L; Meyer C; Kaufmann M; Scherr M; Drexler HG; Macleod RA
Leuk Lymphoma; 2011 Feb; 52(2):290-7. PubMed ID: 21261500
[TBL] [Abstract][Full Text] [Related]
38. Notch Signaling Controls Transcription via the Recruitment of RUNX1 and MYB to Enhancers during T Cell Development.
Rodríguez-Caparrós A; García V; Casal Á; López-Ros J; García-Mariscal A; Tani-Ichi S; Ikuta K; Hernández-Munain C
J Immunol; 2019 Apr; 202(8):2460-2472. PubMed ID: 30877169
[No Abstract] [Full Text] [Related]
39. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.
Yashiro-Ohtani Y; Wang H; Zang C; Arnett KL; Bailis W; Ho Y; Knoechel B; Lanauze C; Louis L; Forsyth KS; Chen S; Chung Y; Schug J; Blobel GA; Liebhaber SA; Bernstein BE; Blacklow SC; Liu XS; Aster JC; Pear WS
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):E4946-53. PubMed ID: 25369933
[TBL] [Abstract][Full Text] [Related]
40. E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.
Pi WC; Wang J; Shimada M; Lin JW; Geng H; Lee YL; Lu R; Li D; Wang GG; Roeder RG; Chen WY
Blood; 2020 Jul; 136(1):11-23. PubMed ID: 32276273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]